Companies › LB Pharmaceuticals
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Psychiatry; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LB-102 Atypical antipsychotic; dopamine D2/D3 receptor antagonist | DRD2, DRD3 | Phase 3 | Schizophrenia; Bipolar I Disorder | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07363577 | LB-102 | Phase 3 | Schizophrenia | Psychiatry | Jun 2027 |
| NCT07494305 | LB-102 | Phase 2 | Bipolar I Disorder | Psychiatry | Feb 2028 |
| NCT07369154 | LB-102 | Phase 3 | Schizophrenia | Psychiatry | Dec 2028 |
Cash and short-term investments of $403m on 2026-09-30; operating cash outflow about $168m a year; runway about 29 months at that burn, to Feb 2029; 3 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Gedeon Richter Reviva Pharmaceuticals Minerva Neurosciences Cybin IRL Beijing Union Pharmaceutical Factory
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.